RECRUITING

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Talk to us

Conditions

Acute LeukemiaLeukemia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

Official Title

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Quick Facts

Study Start:2025-06
Study Completion:2026-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06907797

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 or older
  2. * English speaking
  3. * Ability to understand and willingness to sign written informed consent
  4. * Clinical suspicion of acute leukemia
  5. * Admitted to DFCI-affiliated inpatient unit
  1. * Cognitive impairment rendering the individual unable to participate in beta testing
  2. * This will be assessed by focused chart review and consultation with the patients' inpatient care team.
  3. * The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers \<18 years old), prisoners.
  4. * Inability to participate in in-person application testing.
  5. * Patients who participated in alpha-testing through protocol 23-404 (Appendix A)

Contacts and Locations

Study Contact

Andrew Hantel, MD
CONTACT
617-582-9394
Andrew_hantel@dfci.harvard.edu
Erin Gallagher
CONTACT
857-215-2275
erin_gallagher@dfci.harvard.edu

Principal Investigator

Andrew Hantel, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Andrew Hantel, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06
Study Completion Date2026-12-01

Study Record Updates

Study Start Date2025-06
Study Completion Date2026-12-01

Terms related to this study

Keywords Provided by Researchers

  • Acute Leukemia
  • Leukemia

Additional Relevant MeSH Terms

  • Acute Leukemia
  • Leukemia